Lupin obtains FDA approval, tentative OK for 2 genericsThe Food and Drug Administration approved Lupin’s sevelamer carbonate for oral suspension and gave tentative approval for azilsartan medoxomil tablets. Amneal to acquire Saol Therapeutics’ Baclofen franchiseThe acquisition expands Amneal’s neurology presence into spasticity. U.S. Court of Appeals for the Federal Circuit upholds validity of Novartis’ Gilenya dosage regimen patent Novartis said it expects no generic versions of Gilenya in the U.S. market for at least the next two years. Alembic given FDA OK for generic Doryx Doxycycline hyclate delayed-release tablets have a market value of roughly $10 million for the 12 months ending September 2021, according to IQVIA. Par launches generic Cuvposa The product is indicated to reduce chronic severe drooling in children ages 3 to 16 years old with neurologic conditions that cause abnormal drooling. Teva debuts generic Narcan Teva’s generic Narcan provides a treatment for opioid emergencies. Camber intros generic Adderall XR The medication is indicated for the treatment of attention deficit hyperactivity disorder. Cipla gains FDA blessing for generic Somatuline Depot Somatuline Depot injection has a market value of approximately $867 million for the 12 months ending October 2021, according to IQVIA. Hikma launches bupivacaine HCl injection Bupivacaine HCl injection had a market value of approximately $64 million in the 12 months ending October 2021. Alembic obtains FDA approval, tentative OK for 2 generics The Food and Drug Administration has given Alembic clearance for formoterol fumarate inhalation solution and tentative approval for selexipag tablets in various dosage strengths. First Previous 106 107 108 109 110 Next Last
